4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $45.25 Consensus PT from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $45.25.

Several equities analysts have issued reports on FDMT shares. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Leerink Partners reiterated an “outperform” rating and issued a $36.00 target price (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, July 22nd. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Finally, BMO Capital Markets lowered their price target on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, July 18th.

4D Molecular Therapeutics Trading Up 0.9 %

Shares of 4D Molecular Therapeutics stock opened at $8.53 on Friday. The firm has a market cap of $441.03 million, a P/E ratio of -3.50 and a beta of 2.77. 4D Molecular Therapeutics has a 12 month low of $8.37 and a 12 month high of $36.25. The stock’s fifty day moving average price is $13.03 and its 200-day moving average price is $19.51.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $1.90 million. Analysts forecast that 4D Molecular Therapeutics will post -2.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of FDMT. Goldman Sachs Group Inc. increased its position in shares of 4D Molecular Therapeutics by 415.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock valued at $16,539,000 after buying an additional 658,069 shares in the last quarter. Entropy Technologies LP purchased a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at approximately $239,000. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of 4D Molecular Therapeutics by 10.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 706,000 shares of the company’s stock valued at $14,819,000 after buying an additional 65,000 shares in the last quarter. Kennedy Capital Management LLC purchased a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at approximately $4,358,000. Finally, Sofinnova Investments Inc. increased its position in shares of 4D Molecular Therapeutics by 36.8% in the second quarter. Sofinnova Investments Inc. now owns 271,155 shares of the company’s stock valued at $5,692,000 after buying an additional 72,969 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.